Status:
COMPLETED
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Pfizer
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with t...
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects of non childbearing potential.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Key Trial Info
Start Date :
October 16 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 11 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00989079
Start Date
October 16 2009
End Date
December 11 2009
Last Update
May 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.